Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Piperazine→

Piperazine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
110-85-0
Molecular formula
C4H10N2
Molecular weight
86.14 g/mol
Drug class
Anthelminticnematode GABA-receptor agonist
Mechanism of action
Acts as a GABA-receptor agonist at nematode muscle membranes, increasing chloride conductance and causing flaccid paralysis. The paralysed worms are expelled through normal intestinal peristalsis.
Indications / reported uses
  • Treatment of susceptible intestinal nematode infections, principally ascariasis (roundworm) and enterobiasis (pinworm), where piperazine remains authorised.

Sources: https://pubchem.ncbi.nlm.nih.gov/compounds/4837 · https://pubmed.ncbi.nlm.nih.gov/9265850/ · https://applications.emro.who.int/docs/em_pharm_96_en.pdf · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Piperazine Environmental Risk Assessment (ERA) (the Piperazine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.